Comparison · NCT03643965-4b209f3a
Nefecon vs Placebo Oral Capsule: Part B: Proportion of Patients Without Microhematuria
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Nefecon vs Placebo Oral Capsule: Part B: Proportion of Patients Without Microhematuria. Trial comparisons, record NCT03643965-4b209f3a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03643965-4b209f3a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.516 | 0.444 | 0.588 | wilson | |
| Risk in group 2 | 0.324 | 0.26 | 0.395 | wilson | |
| Risk difference, group 1 minus group 2 | 0.192 | 0.091 | 0.288 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.59 | 1.24 | 2.05 | log | |
| Odds ratio, group 1 over group 2 | 2.23 | 1.46 | 3.41 | log | |
| Number needed to treat, for one more participant with the outcome on Nefecon than on Placebo Oral Capsule | 5.2 | 3.47 | 11 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Nefecon | Nefecon 16 mg once daily by mouth for 9 months.~Nefecon: Nefecon 16 mg for daily administration by mouth for 9 months. | 94 | 182 | OG000 |
| Group 2 | Placebo Oral Capsule | Placebo oral capsule once daily by mouth for 9 months.~Placebo oral capsule: Placebo capsules for daily administration by mouth for 9 months. | 59 | 182 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Part B: Proportion of Patients Without Microhematuria
- Description
- Part B: Proportion of patients without microhematuria in at least 2 of the following time points: 12, 18, and 24 months following the first dose of study drug
- Time frame
- 12 to 24 months
- Population
- Full analysis set - global study - Part B
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy
- NCT number
- NCT03643965
- Phases
- PHASE3
- Conditions
- Primary IgA Nephropathy
- Interventions
- Nefecon, Placebo oral capsule
- Lead sponsor
- Calliditas Therapeutics AB
- Results first posted
- 2024-12-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03643965?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03643965-4b209f3a